Barclays’s Altimmune ALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $594K | Sell |
192,871
-207,724
| -52% | -$882K | ﹤0.01% | 3082 |
|
|
2025
Q4 | $1.45M | Buy |
400,595
+60,312
| +18% | +$263K | ﹤0.01% | 3171 |
|
|
2025
Q3 | $1.28M | Buy |
340,283
+48,188
| +16% | +$186K | ﹤0.01% | 3214 |
|
|
2025
Q2 | $1.13M | Buy |
292,095
+104,633
| +56% | +$566K | ﹤0.01% | 3262 |
|
|
2025
Q1 | $937K | Buy |
187,462
+29,934
| +19% | +$190K | ﹤0.01% | 3151 |
|
|
2024
Q4 | $1.14M | Buy |
157,528
+1,787
| +1% | +$13.7K | ﹤0.01% | 3292 |
|
|
2024
Q3 | $956K | Buy |
155,741
+75,064
| +93% | +$509K | ﹤0.01% | 3384 |
|
|
2024
Q2 | $537K | Sell |
80,677
-19,678
| -20% | -$145K | ﹤0.01% | 3003 |
|
|
2024
Q1 | $1.02M | Buy |
100,355
+27,932
| +39% | +$284K | ﹤0.01% | 3103 |
|
|
2023
Q4 | $815K | Sell |
72,423
-107,986
| -60% | -$451K | ﹤0.01% | 3597 |
|
|
2023
Q3 | $469K | Buy |
180,409
+69,014
| +62% | +$198K | ﹤0.01% | 2846 |
|
|
2023
Q2 | $393K | Sell |
111,395
-115,466
| -51% | -$518K | ﹤0.01% | 2898 |
|
|
2023
Q1 | $957K | Sell |
226,861
-134,380
| -37% | -$1.6M | ﹤0.01% | 2763 |
|
|
2022
Q4 | $5.94M | Buy |
361,241
+173,277
| +92% | +$1.95M | ﹤0.01% | 1497 |
|
|
2022
Q3 | $2.4M | Sell |
187,964
-877,583
| -82% | -$13M | ﹤0.01% | 1621 |
|
|
2022
Q2 | $12.5M | Sell |
1,065,547
-89,734
| -8% | -$553K | 0.01% | 923 |
|
|
2022
Q1 | $7.04M | Buy |
1,155,281
+60,221
| +5% | +$443K | 0.01% | 1064 |
|
|
2021
Q4 | $10M | Buy |
1,095,060
+812,041
| +287% | +$8.63M | ﹤0.01% | 1269 |
|
|
2021
Q3 | $3.2M | Buy |
283,019
+215,047
| +316% | +$2.62M | ﹤0.01% | 1959 |
|
|
2021
Q2 | $670K | Buy |
67,972
+35,127
| +107% | +$480K | ﹤0.01% | 2901 |
|
|
2021
Q1 | $464K | Buy |
32,845
+4,545
| +16% | +$73.5K | ﹤0.01% | 3224 |
|
|
2020
Q4 | $319K | Buy |
28,300
+100
| +0.4% | +$1.18K | ﹤0.01% | 3516 |
|
|
2020
Q3 | $372K | Sell |
28,200
-91,515
| -76% | -$1.83M | ﹤0.01% | 3440 |
|
|
2020
Q2 | $1.28M | Buy |
+119,715
| New | +$658K | ﹤0.01% | 2531 |
|
|
2018
Q2 | – | Sell |
-1
| Closed | – | – | 6935 |
|
|
2018
Q1 | $0 | Buy |
+1
| New | +$50 | ﹤0.01% | 7018 |
|
|
2017
Q3 | – | Sell |
-109
| Closed | -$10K | – | 6820 |
|
|
2017
Q2 | $10K | Buy |
109
+94
| +627% | +$15.6K | ﹤0.01% | 6046 |
|
|
2017
Q1 | $3K | Buy |
+15
| New | +$8.03K | ﹤0.01% | 6376 |
|
|
2016
Q4 | – | Sell |
-1
| Closed | -$1K | – | 6579 |
|
|
2016
Q3 | $1K | Buy |
+1
| New | +$784 | ﹤0.01% | 6357 |
|
|
2016
Q2 | – | Sell |
-5
| Closed | -$1K | – | 6298 |
|
|
2016
Q1 | $1K | Buy |
+5
| New | +$2.56K | ﹤0.01% | 5941 |
|
|
2014
Q3 | – | Hold |
0
| – | – | – | 7635 |
|
|
2014
Q2 | – | Hold |
0
| – | – | – | 7580 |
|
|
2014
Q1 | – | Hold |
0
| – | – | – | 7555 |
|
|
2013
Q4 | – | Hold |
0
| – | – | – | 7511 |
|
|
2013
Q3 | – | Sell |
-5
| Closed | -$2.87K | – | 7378 |
|
|
2013
Q2 | $2K | Buy |
+5
| New | +$2.48K | ﹤0.01% | 7510 |
|
Other funds holding ALT
VCM
VPM
N
Barclays's ALT Position: Q1 2026 in Review
Barclays reduced its Altimmune (ALT) stake by 52% in Q1 2026, selling an estimated $882K and leaving 192,871 shares worth $594K. The position accounts for ﹤0.01% of the portfolio, ranked #3082.
Barclays first reported a position in ALT in Q2 2013 and has held it in 30 quarters since. The position peaked at $12.5M in Q2 2022. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.
- Barclays held 192,871 shares of Altimmune worth $594K as of Q1 2026.
- Barclays sold 207,724 Altimmune shares in Q1 2026, an estimated $882K.
- Altimmune made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3082 holding.
- Barclays first reported a position in Altimmune in Q2 2013 and has held it in 30 quarters since.
- Barclays's Altimmune position peaked at $12.5M in Q2 2022.
- 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.